Coronary artery disease (CAD) is the number one cause of death among men and women in the USA. Genetic predisposition and environmental factors lead to the development of atherosclerotic plaques in the vessel walls of the coronary arteries, resulting in decreased myocardial perfusion. Treatment includes a combination of revascularization procedures and medical therapy. Because of the high surgical risk of many of the patients undergoing revascularization procedures, medical therapies to reduce ischemic disease are an area of active research. Small molecule, cytokine, endothelial progenitor cell, stem cell, gene, and mechanical therapies show promise in increasing the collateral growth of blood vessels, thereby reducing myocardial ischemia. Coron Artery Dis 28:605-613
Introduction
Coronary artery disease (CAD) is the number one cause of death among men and women in the USA [1, 2] . Genetic predisposition and environmental factors lead to the development of atherosclerotic plaques in the vessel walls of the coronary arteries, resulting in decreased myocardial perfusion. Current diagnostic modalities for CAD start with noninvasive studies to determine myocardial function. If ischemic disease is suspected, coronary angiography is the current standard of care to evaluate the atherosclerotic disease. Treatment includes a combination of revascularization procedures and medical therapy. Because of the high surgical risk of many of the patients undergoing revascularization procedures, medical therapies to reduce ischemic disease are an area of active research.
Pathophysiology of coronary vascular disease
Both genetic predisposition and environmental factors contribute toward a pro atherogenic environment leading to the development of CAD [1] . Although many genes have been identified to be associated with ischemic heart disease, it is clear that genetic predisposition is not acting alone. Current research suggests that the microbiome of the gastrointestinal tract may also play a role by breaking down certain cytokines [1] . Environmental factors that contribute toward the development include smoking history, poor diet, and a sedentary lifestyle.
Patients with ischemia heart disease often have comorbidities that include insulin intolerance, hyperlipidemia, hypertension, hyperglycemia, and obesity. Together, these comorbidities individually serve as proatherogenic stimuli and are known as the pathology of metabolic syndrome. Proatherogenic stimuli induce inflammation and altered platelet function leading to abnormalities in the endothelial barrier, which leads to increased vascular permeability. This increased vascular permeability facilitates transendothelial migration of immune cells to the arterial intima and induction of vascular inflammation. This inflammation leads to destabilization of the cellular wall integrity, and accumulation of platelet and fat-laden macrophages, resulting in the development of an atherosclerotic plaque in the vessel wall and decreased perfusion to the heart [1, 3, 4] . transforming growth factor-β, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), granulocyte macrophage stimulating factor, and others [5, 8] . These cytokines, endothelial progenitor cells, and certain genes are the target of current research aiming to alleviate the pathogenesis of CAD.
Significant clinical trial/registry data
Research in cardiovascular disease is at the forefront of the medical field (Table 1) . Breakthrough drugs such as clopidogrel have altered the long-term outcomes for patients with CAD. The prognostic significance of collateral circulation has been proven to be beneficial in recent clinical trials. Patients with high collateral blood flow have lower all-cause mortality and cardiac mortality compared with patients with low collateral blood flow [9] [10] [11] [12] [13] [14] [15] . Therapeutic angiogenesis refers to the concept that angiogenic growth factors can stimulate the development of collateral arteries and improve patient outcomes.
The FGF Initiation Revascularization Trial (FIRST) evaluated the efficacy and safety of recombinant FGF-2 as a single bolus intracoronary administration to improve symptoms and myocardial function. The study found that a single intracoronary infusion of FGF-2 does not improve exercise tolerance or myocardial perfusion, but does show trends toward symptomatic improvement at 90 (but not 180) days [16] . The Angiogenic Gene Therapy (AGENT) trial evaluated the safety and anti-ischemic effects of five doses of adenovirus containing a human FGF gene in patients with stable angina pectoris. Patients who received the treatment showed greater improvements in exercise time at 4 weeks and no adverse reactions were encountered. The study determined that adenovirus containing a human FGF gene is shown to be effective and safe as a therapy [17] .
Stem cell therapy is a promising approach in patients with CAD [18, 19] . However, a Cochrane review performed in 2012 on the effectiveness of adult bone marrow-derived stem cells to treat acute myocardial infarction (MI) concluded that only moderate improvement in global heart function is significant and sustainable on a long-term basis. Furthermore, there was a high degree of heterogeneity between studies [20] . Current stem cell research focuses on optimization of cell therapy by improving cellular homing, combining cell regimens, and using resident cell populations. Cardiopoietic cells are produced through cardiogenic conditioning of patient-derived mesenchymal cells, resulting in stem cells that have enhanced cardioreparative functionality [21, 22] . Preclinical ischemic heart failure models suggest that cardiopoietic stem cell therapy improves left ventricular functioning and improves myocardial remodeling. The Cardiopoietic stem Cell therapy in heart failURE (C-CURE) evaluated the feasibility and safety of cardiopoietic cell therapy in patients with ischemic heart failure and concluded that cardiopoietic stem cell therapy merited definitive clinical evaluation [22] . The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial evaluated the efficacy of cardiopoietic cell biotherapy (vs. a sham procedure) in patients with advanced ischemic heart failure and determined that there was no difference in the Finkelstein-Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. Further analysis suggested that there is a benefit of cardiopoietic cell therapy in patients with elevated baseline left ventricular end-diastolic volume (200-379 ml). There was no difference in adverse effects. The review concluded that the evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume as a result of ischemic disease should be studied further [21] .
To date, there have been no successful therapeutic angiogenesis clinical trials to induce functional collateral vessel growth that is associated with improved myocardial function.
Diagnostic strategies
There are extensive ACC/AHA Guidelines on appropriate diagnostic, interventional, and medical treatment of patients with CAD. In terms of the strength of recommendation, there are five classes: I (strong), IIa (moderate), IIb (weak), III no benefit (moderate), and III harm (strong). The current guidelines for diagnostic and therapeutic strategies will be discussed briefly.
Noninvasive diagnostic testing
The National Institute for Health and Care Excellences Clinical Guideline assessed the performance and cost utility of different noninvasive imaging strategies in patients presenting with chest pain and determined that the low cost and high sensitivity of the cardiac computed tomography make it the noninvasive test of choice [23] . Other modalities for nondiagnostic workup include rest echocardiography, ECG, and stress testing.
Invasive diagnostic testing
Coronary angiography is considered the gold standard for the diagnosis of CAD. However, its major shortcoming is that it cannot assess the physiological significance of lesions or the stability of the plaque. In addition, interventional studies have a 1.5% incidence of procedural complications including death, stroke, bleeding, infection, myocardial infarction, anaphylactic reactions, nephropathy, vascular damage, arrhythmias, and need for immediate revascularization. Despite these shortcomings, coronary angiography is useful in patients with presumed stable ischemic heart disease (SIHD) who have unacceptable Table 1 Trials in coronary angiogenesis AGENT, Angiogenic Gene Therapy; C-CURE, Cardiopoietic stem Cell therapy in heart failure; CHART-1, Congestive Heart Failure Cardiopoietic Regenerative Therapy; FGF-2, fibroblast growth factor 2.
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ischemic symptoms despite guideline-directed medical treatment and who are amenable to, and candidates for, coronary revascularization (class I) [24] . Coronary angiography is also useful when noninvasive tests yield ambiguous or indeterminate results.
The International Study of Comparative Health Effectiveness With Medical And Invasive Approaches (ISCHEMIA) trial is currently randomizing patients with moderate ischemia on stress testing to a strategy of optimal medical therapy alone (with coronary angiography reserved for failure of medical therapy) or routing cardiac catheterization, followed by revascularization (when appropriate) plus optical medical therapy. Before randomization, patients with normal renal function undergo a blinded computed tomography angiography to exclude them if significant left main CAD or no significant CAD is present. The ISCHEMIA trial will provide evidence on the optimal strategy for managing patients with nonleft main SIHD and moderate to severe ischemia [24] .
Therapeutic strategies Current revascularization therapy
In the setting of severe ischemia, disease revascularization has been proven to improve survival compared with medical therapy alone [25] . Depending on the extent of their disease, patients will undergo a coronary artery bypass grafting (CABG) alone, a CABG and percutaneous intervention (PCI), PCI alone, or no revascularization procedure at all. Irrespective of the revascularization procedure performed, all patients require medical therapy.
Current medical therapy
Class 1 recommendation states that patients with CAD should be on aspirin (100-325 mg daily), β-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers and smoking cessation [26] . Class II recommendation suggests that patients with CAD and acute coronary syndrome (ACS) benefit from statin use. Patients with a history of ACS greater than 1 year who have remained free of recurrent ACS are considered to have transitioned to SIHD [27] .
Patients with acute disease should be treated in one of four ways: (I) with medical therapy, (II) with lytic therapy, (III) with PCI [bare-metal stent (BMS) or drugeluting stent (DES)], or (IV) with CABG. 
Research for novel therapeutic angiogenesis strategies
Therapeutic angiogenesis is a popular area of research because of the large patient population that has coronary vascular disease and the high mortality rate of patients with coronary vascular disease. Many of the clinical trials involving drugs that were successful in animal models are not successful in phase I clinical trials. One reason for this failure to translate from animal models into human populations is that most animal models induce coronary ischemia alone. However, it is well known that patients who have coronary vascular disease also have metabolic syndrome. The individual aspects of metabolic syndrome contribute toward endothelial dysfunction and intensify the coronary disease present in these patients. Therefore, an ideal animal model will induce not only coronary vascular disease but also metabolic syndrome.
Small molecule therapy
Recently, there have been a number of small molecules that have been successfully shown to induce a functional neovasculature in the setting of ischemia [28, 29] . In a pig model of chronic myocardial ischemia in the setting of diet-induced metabolic syndrome, calpain inhibition has been shown to improve myocardial perfusion, increase endothelialdependent microvascular relaxation, decrease apoptosis, and improve oxidative stress in ischemic myocardial tissue [30] [31] [32] .
In the same pig model, a downstream molecular target of calpain, glycogen synthase kinase-3B, inhibition was found to have the same beneficial effects [33] .
Neuropeptide Y serves as a neurotransmitter that is associated with stress, diet, and fat accumulation. In a pig model of diet-induced metabolic syndrome and chronic coronary ischemia, neuropeptide-Y injection into the area of ischemia was found to improve collateral vessel growth and increase angiogenesis and myocardial perfusion and function [34] .
Cytokine therapy
Monocyte activation plays a major role in angiogenesis and collateral artery growth through FGF and VEGF mediated pathways [35] [36] [37] [38] . Monocyte chemoattractant protein-1 expression on leukocytes, predominantly macrophages, increases the progression of atherosclerosis by increasing macrophage numbers and oxidizing lipid accumulation [39] . Granulocyte macrophage colonystimulating factor injection into patients with patients with both chronic stable and stenotic CAD has been found to be effective in promoting coronary collateral artery growth and improving myocardial function [15, [40] [41] [42] . However, granulocyte macrophage colony-stimulating factor was also found to induce the development of acute coronary syndrome, making its safety questionable. VEGF therapy has been found to increase macrophage levels in the bone marrow and peripheral blood, but was also shown to increase plaque progression in cholesterol-fed mice and rabbits, making its efficacy for clinical use questionable [43] .
Endothelial progenitor cell therapy
Endothelial progenitor cells (EPCs) are considered to serve as a biological marker for vascular function and cumulative cardiovascular risk [44] . An injection of endothelial cell has been shown to inhibit neo intimal hyperplasia after arterial injury and to mobilize EPCs to the neoendothelium [45] . In a mouse model of left anterior descending coronary artery ligation, samples of sites of myocardial infarction show endothelial progenitor cell incorporation in foci of neovascularization at the border of the infarct. These findings suggest that postnatal neovascularization does not solely rely on sprouting from pre-existing blood vessels but also stems from endothelial progenitor cells that circulate from the bone marrow to incorporate into and contribute toward neovascularization [46] . Endothelial progenitor cells are found at sites of tissue injury and differentiate into mature endothelial cells. Spleen-derived EPCs from healthy rats injected into rats with inflammatory-mediated cardiomyopathy resulted in functional improvements in cardiac Treatment algorithm of patients with acute disease. 1. P2Y12 inhibitor may be stopped after 3 months of SIHD if no ACS, or 6 months of SIHD in the event of ACS. ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; PCI, percutaneous intervention; SIHD, stable ischemic heart disease.
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muscle, reduced scar tissue, and thickened ventricular walls in rats receiving the injection compared with untreated animals [47] . Vascular endothelial growth factor modulates postnatal endothelial progenitor cell kinetics [48] . Patients with unstable angina and no evidence of cardiac stenosis and patients with stable angina were evaluated for circulating EPC numbers. The patients in the experimental group showed an increased number of circulating EPCs [49] .
Stem cell therapy
Stem cell therapy is a promising therapeutic approach to reduce myocardial ischemia. Progenitor cells from the saphenous vein of patients undergoing coronary artery bypass surgery established N-cadherin-mediated physical contact with capillary endothelium and improved neovascularization and blood flow recovery in ischemic limbs of immunodeficient mice [50] .
Autologous transplantation to grow an artificial blood conduit of any required length and diameter from the cells of the host for autologous transplantation is currently under research. Silastic tubing is inserted into the peritoneal cavity of rats or rabbits. The tubing becomes covered in myofibroblasts, collagen matrix, and mesothelium. The silastic tubing is then removed and the implants are inverted; thus, the inner lining consists of a nonthrombotic mesothelial cell 'intima' with a new myofibroblast-like 'media' and a collagen and elastin outer 'adventitia' layer. The new vessel is then anastomosed to the carotid artery or the abdominal aorta of the same animal in which they were grown remain patent for at least 4 months. These neovessels develop structures resembling elastic lamellae and myofibroblasts increase in counts and function to contract [51] . Further research is needed to determine the long-term efficacy of these neo vessels.
A Cochrane Review evaluating the effectiveness of adult bone marrow-derived stem cells to treat acute myocardial infarction found that despite the high degree of heterogeneity between studies, bone marrow-derived stem cells are effective in inducing improvement in global heart function. However, a larger number of participants is required [20] .
Gene therapy
Cardiac gene therapy is a promising technique that will enable effective clinical delivery of gene therapy to the heart. The development of bioengineered recombinant viruses that specifically target the myocardium in addition to advances in the selection and design of the genetic target are currently being tested in preclinical models of heart disease [52] [53] [54] [55] [56] [57] [58] [59] . Catheterbased percutaneous transluminal gene delivery into coronary arteries has been used in pig models to present gene therapy to ischemic myocardial tissue by retrograde delivery into the anterior cardiac vein [57, 60, 61] . Kaminksy et al. [62] studied the safety profile of AdVEGF-AII6A+ (an AD5 vector expression of a cDNA/genomic hybrid of vascular endothelial growth factor (isoforms 121, 165 and 189) in an adult rat ischemia heart model to support the initiation of a clinical study to treat humans with diffuse CAD. The study concluded that AdVEGF-AII6A + was safe to proceed to clinical trial [62] . [63] . Gene therapy is a promising new approach to ischemic disease [64] . However, future work is needed to determine the most appropriate route of delivery and the best gene to target.
Mechanical therapy
The introduction of mechanical therapy to induce collateral vessel growth is a recent area of research. Transmyocardial laser revascularization (TMLR) has been proposed to improve symptoms of chronic angina in patients with advanced CAD. Transmyocardial laser revascularization is a surgical intervention that uses a laser device directly on the heart surface to re-establish blood flow in certain areas of the heart. Its intended use is on patients who have severe CAD with poor quality of life who are not candidates for revascularization procedures. A Cochrane Review published in February of 2015 assessed the effects of TMLR versus optimal medical treatment in patients with refractory angina who are not candidates for revascularization procedures to alleviate angina severity, reduce mortality, and improve ejection fraction. The review established that there was no difference in survival between groups and that there was a significant increase in postoperative mortality and other safety outcomes after TMLR therapy versus the control. Therefore, the review concluded that the risks of TMLR therapy outweigh the potential clinical benefits [65] .
New devices to mechanically induce collateral growth are currently under investigation. Enhanced external counterpulsation treatment has been found to reduce angina, stimulate coronary arteriogenesis, and extend time to exercise-induced ischemia in patients with symptomatic CAD [12, [66] [67] [68] . In addition, increased coronary sinus pressure can reduce myocardial ischemia by redistribution of blood from nonischemic to ischemic territories. A coronary sinus reducer is a percutaneous implantable device designed to establish coronary sinus narrowing and to elevate coronary sinus pressure. It has been found to improve angina score, reduce stress induced ST-segment depression, and alleviate the extent and severity of myocardial ischemia by dobutamine echocardiography and by thallium singlephoton emission computed tomography (Fig. 3 ) [69] .
Conclusion
There have been huge breakthroughs in cardiovascular treatment in the last decade both with interventional and with medical therapies. However, because of the large numbers of patients with cardiovascular disease and the high morbidity and mortality associated with it, new medical therapies to reduce ischemic disease will continue to change the way we treat patients (Table 2) . Novel Molecular Therapies for The Treatment of Ischemic Heart Disease. Flow diagram showing the new molecular therapies. GM-CSF, granulocyte macrophage stimulating factor; VEGF, vascular endothelial growth factor.
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Therapeutic angiogenesis is an active area of research. Small molecule, cytokine, endothelial progenitor cell, stem cell, gene, and mechanical therapies show promise in increasing the collateral growth of blood vessels, thereby reducing myocardial ischemia. 
